There is now a greater understanding of the molecular pathways in ovarian cancer, and using this knowledge, a large number of new therapeutic agents can be tested. The success of these drugs will depend on selecting drugs that target known key dysfunctional molecular pathways. To make best use of these compounds, prognostic and predictive biomarkers need to be identified. Novel methods of assessment such as functional imaging need to be developed as additional biological end points to evaluate these therapies. Promising antitumor activity has been observed with some drugs, and careful consideration is needed to determine in what circumstances new agents, such as antiangiogenic compounds, could be considered as a standard therapy. These areas were discussed at the 4th Ovarian Cancer Consensus Conference.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/IGC.0b013e31821b2669 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Purpose: To provide updated guidance regarding neoadjuvant chemotherapy (NACT) and primary cytoreductive surgery (PCS) among patients with stage III-IV epithelial ovarian, fallopian tube, or primary peritoneal cancer (epithelial ovarian cancer [EOC]).
Methods: A multidisciplinary Expert Panel convened and updated the systematic review.
Results: Sixty-one studies form the evidence base.
Purpose: Clinical variables alone have limited ability to determine which patients will have recurrence after radical prostatectomy (RP). We evaluated the ability of locked multimodal artificial intelligence (MMAI) algorithms trained on prostate biopsy specimens to predict prostate cancer specific mortality (PCSM) and overall survival (OS) among patients undergoing radical prostatectomy with digitized RP specimens.
Materials And Methods: The Prostate, Lung, Colorectal, and Ovarian Cancer Screening Randomized Controlled Trial randomized subjects from 1993-2001 to cancer screening or control.
An overview of the use of cutting-edge artificial intelligence (AI) modeling to produce synthetic medical data (SMD) in decentralized clinical machine learning (ML) for ovarian cancer(OC) and ovarian lymphoma(OL).
J Ultrasound
January 2025
, Costa Contina street n. 19, 66054, Vasto, Chieti, Italy.
Aim: o point out how novel analysis tools of AI can make sense of the data acquired during OL and OC diagnosis and treatment in an effort to help improve and standardize the patient pathway for these disease.
Material And Methods: ultilizing programmed detection of heterogeneus OL and OC habitats through radiomics and correlate to imaging based tumor grading plus a literature review.
Results: new analysis pipelines have been generated for integrating imaging and patient demographic data and identify new multi-omic biomarkers of response prediction and tumour grading using cutting-edge artificial intelligence (AI) in OL and OC.
Predicting Postoperative Infection After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy with Splenectomy.
Ann Surg Oncol
January 2025
Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Background: Hematologic changes after splenectomy and hyperthermic intraperitoneal chemotherapy (HIPEC) can complicate postoperative assessment of infection. This study aimed to develop a machine-learning model to predict postoperative infection after cytoreductive surgery (CRS) and HIPEC with splenectomy.
Methods: The study enrolled patients in the national TriNetX database and at the Johns Hopkins Hospital (JHH) who underwent splenectomy during CRS/HIPEC from 2010 to 2024.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!